Bausch + Lomb vs Caris Life Sciences

Bausch + Lomb (BLCO), health care, and Caris Life Sciences (CAI), health care, side by side on market value, valuation, margins, balance sheet and price change. Higher and lower are marked; neither is called better.

Bausch + Lomb is worth $7.4B on the stock market and Caris Life Sciences $5.7B: Bausch + Lomb is valued at 30% more. Bausch + Lomb's operating margin in its latest fiscal year was 2.22% and Caris Life Sciences's 5.56%. Over the past year Bausch + Lomb's share price has moved +38.3% and Caris Life Sciences's -11.6%.

Key facts

Bausch + Lomb market value
$7.4B
Caris Life Sciences market value
$5.7B
Caris Life Sciences P/E
12.0
Bausch + Lomb revenue
$5.1BFY to 2025-12-31
Caris Life Sciences revenue
$812MFY to 2025-12-31
Superinvestors holding both
0

Market values as of .

Bausch + Lomb vs Caris Life Sciences: every measure side by side
Measure Bausch + Lomb Caris Life Sciences
SectorHealth CareHealth Care
Country Canada United States
Fiscal year ends2025-12-312025-12-31
Size
Market cap$7.4Bhigher$5.7Blower
Revenue$5.1Bhigher$812Mlower
Earnings-$360Mlower-$68.1Mhigher
Employees13,000higher1,846lower
Total assets$14Bhigher$1.1Blower
Valuation
P/E—12.0
P/S1.5lower7.0higher
P/B—8.9
Dividend yield—0.00%
Profitability
Operating margin2.22%lower5.56%higher
Balance sheet
Net assets$6.4Bhigher$577.3Mlower
Total liabilities$7.5Bhigher$548.4Mlower
Total debt$5Bhigher$379Mlower
Cash on hand$383Mlower$796.3Mhigher
Price change
Today-0.24%higher-5.05%lower
1 year+38.3%higher-11.6%lower

Market value, P/E, P/B, dividend yield and price changes are from live quotes (Yahoo Finance; prices may be delayed 15 minutes or more). Revenue, earnings, operating margin and the balance-sheet figures are from each company's latest annual report filed with the SEC (collected 2026-11-12); a company that reports in another currency is converted to US dollars at the exchange rate of that day. P/S sets today's market value against the latest fiscal year's revenue. “Higher” and “lower” compare the two numbers only; a higher P/E or more debt is not better. Dividend yield and P/B are shown only for companies based in the US. A dash means no figure is on file.

Loading the one-year price chart…

Which superinvestors hold them

From each tracked investor's latest 13F filing. A 13F lists long positions in US-listed shares at a quarter end, filed up to 45 days later.

Both (0)

None of the tracked investors.

Bausch + Lomb only (4)

Caris Life Sciences only (2)

Percentages are each holding's share of that investor's reported portfolio. Who owns BLCO · Who owns CAI

Further comparisons

Learn

Questions and answers

Which is bigger, Bausch + Lomb or Caris Life Sciences?

By market value, Bausch + Lomb is the larger: $7.4B against $5.7B for Caris Life Sciences. By revenue in its latest fiscal year, Bausch + Lomb is the larger: $5.1B against $812M for Caris Life Sciences.

Which has the higher operating margin?

Caris Life Sciences: 5.56%, against 2.22% for Bausch + Lomb. Operating margin is operating income as a share of revenue in the latest fiscal year.

Which has more debt?

Bausch + Lomb: $5B, against $379M for Caris Life Sciences. Total debt is borrowings at the end of the latest fiscal year, as each company reported it; it is not set against cash here.

Which superinvestors own both Bausch + Lomb and Caris Life Sciences?

None of the tracked superinvestors holds both in their latest 13F filing. 4 hold Bausch + Lomb and 2 hold Caris Life Sciences.

Cite this page

Funkfolio, “Bausch + Lomb vs Caris Life Sciences”, data as of 18 November 2026. https://funkfolio.com/compare/blco-vs-cai

Underlying data: Yahoo Finance quotes; SEC annual reports collected 2026-11-12; 13F filings.